Navigation Links
Biocon to Launch Anti-arthritis Drug

New Delhi: India's leading biotech firm Biocon Monday said it would launch in the next three-four years a new anti-arthritis drug which would have the potential to "be a// multi-billion dollar opportunity for the company".

"The new molecule (T1H) which has completed phase II of clinical trials can prove to be a multi-billion opportunity for us," said Kiran Mazumdar Shaw, chairman and managing director of Biocon Ltd, on the sidelines of the 22nd Indian Economic Summit here.

"Phase III of the trails will start within the next 18 months and for that we are looking at global partners," she added.

The company is also looking at earning revenue of about $100 million from the recent cancer drug BIOMAb-EGFR, mainly from the Middle East market.

Biocon launched BIOMAb-EGFR last month for treating solid tumours of epithelial origin, such as head and neck cancers.

Source-IANS
'"/>




Page: 1

Related medicine news :

1. Biocon to colloborate for development of Oral peptide drugs for heart diseases.
2. Biocon To Raise Its Investment In Scotland
3. Biocon To Shift Focus On Innovation To Accelerate Growth
4. Kalam Dedicates New Cancer Drug Developed By Biocon
5. Bayer to Market Biocon Insulin in China
6. Biocon Launches Anti-Cancer Drug
7. Biocon Unveils Renal Therapies for Kidney Disorders
8. Biocon Net Profit Up by 15 Percent for Fiscal Year
9. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
10. Nutrient Profiling System Launched By Food Officials in UK
11. New Oat And Soy-Based Fat Replacer Launched
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Biocon Launch Anti arthritis Drug

(Date:10/10/2008)... MILWAUKEE, Wis., Oct. 10 /PRNewswire/ -- More...the November presidential election. This is the,re...ives held on Thursday,Oct. 9, at all of the healt...sin. A total of 658 people signed up to vote at th...ere trained by the Wisconsin,Government Accountabi...
(Date:10/10/2008)... BEDFORD, Mass., Oct. 10 /PRNewswire-FirstCall...eloper, manufacturer and supplier of premium,diagn...cts dedicated to,serving the healthcare needs of w...quarter and fiscal 2008 operating results on Tuesd...nction with the release, management will,host a co...
(Date:10/10/2008)..., Upon the completion of ...BS Division of CDM Media proudly announces their n...or chief information technology executives in heal... Summit will launch May 10-12, 2009 at the Four Se... Honolulu, HI (PRWEB) October 11, 2008 -- ...
(Date:10/10/2008)... PARK CITY, Utah, Oct. 10 /PRNewswire/ -- NuVi...e management of Trace Life Sciences Inc.,(Trace), ... cyclotron,production facilities in Denton, Texas...., Indium-111, Iodine-123 and Thallium-201 used in,..., NuView Chairman and,CEO, stated that "We are con...
Breaking Medicine News(10 mins):Health News:Hologic, Inc. To Release Fourth Quarter and Fiscal 2008 Operating Results on Tuesday, November 11, 2008 2Health News:CIO Healthcare Summit Announces Dates and VIP Delegates 2
...the advice about healthy diet, good sleep and exer...est beauty secret for a 'sparkling' complexion//. ...in this Rajasthan capital where more and more beau... 'bhasm' (ash) of stones like rubies, emeralds, pe...
...cale to measure the presence and severity of invol...n Parkinson's disease is being developed// and a c...y the Michael J. Fox Foundation for this purpose. ...sia Rating Scale will provide a critical research ...
... a dental health chief to give leadership and impl...l caries among children by 2026, says a British ex...lobal Child Dental Health Taskforce programme in I...mong children in the next 20 years, we need a good...
... reported that doctors from the Michigan State Uni...reatment plan, which allows a more effective// mea... people suffering from symptoms and conditions tha...mith, a physician and professor in MSU’s Departmen...
Other Medicine News:Health News:Astro Gem Therapy: The Latest Beauty Secret for Glowing Skin 2Health News:New Method For Measuring Dyskinesia In Parkinson's Being Developed 2Health News:New Method For Measuring Dyskinesia In Parkinson's Being Developed 3Health News:India needs dental health leadership, says expert 2Health News:India needs dental health leadership, says expert 3Health News:Revolutionary New Treatment Plan Developed For Treatment Of Unexplained Symptoms 2
(Date:10/9/2008)...op Line Clinical Results Expected in November 2008...- SCOLR Pharma, Inc.,(Amex: DDD ) announced today...or the third of its three pivotal trials to evalua...2-hour extended-release (ER) ibuprofen for,the ove... report top-line,results from this pivotal trial i...
(Date:10/8/2008)...cceptance Will Reduce Animal Use in Cosmetics and ...wire/ -- MatTek Corp. today announced,that results...oratory,"catch-up" validation study on MatTek,s Ep...est results demonstrated the required sensitivity ...lidated alternative to animal,testing for determin...
(Date:10/8/2008)... Cornell University Food Scientists Expand Testing...Activity Assay, PORTLAND, Maine, Oct. 8 /PRNewswi...d today with the release of results from a new stu...ther commonly consumed,fruits like apples, bananas...using the Cellular Antioxidant Activity (CAA) assa...
(Date:10/8/2008)... Exploratory study shows clinical improvement in ... (PAH), -- Current treatment options have limit...gressive and incurable blood vessel disease, -- ...eatment of certain cancers, known to inhibit ...ther explore potential of imatinib mesylate in PAH...
Breaking Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 2Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 3Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 4Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 5Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 6Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 7Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 8Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 9Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 10Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 11Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease 12Researchers explore the antidepressant effects of ketamine 12404 1Researchers explore the antidepressant effects of ketamine 12404 2A device that measures optimum state of an organ prior to transplanting has been patented 12401 1A device that measures optimum state of an organ prior to transplanting has been patented 12401 2National Lung Cancer partnership 12400 1National Lung Cancer partnership 12400 2Cleveland Clinic Collaborates with Google 12397 1Cleveland Clinic Collaborates with Google 12397 2Cleveland Clinic Collaborates with Google 12397 3Cleveland Clinic Collaborates with Google 12397 4
...Up to 88% Efficacy, SEOUL, Korea, March 28, 2007 /...d today that it has completed a 340 patient phase,...long acting (12,hour half-life) oral phosphodieste...ion (ED). The multi-center study conducted in the,...olled study,designed to investigate the efficacy ...
...medical and economic advantages of nifedipine,GITS...7 – Two recently,published articles in the J...idence that the use of the long-acting calcium cha...has additional,benefits beyond its blood pressure ...al. (Journal of Clinical Epidemiology,2007; first ...
Other Medicine Technology:Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil,Its New Long Acting Drug For Erectile Dysfunction 2Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil,Its New Long Acting Drug For Erectile Dysfunction 3Dong-A PharmTech Co., Ltd. Announces Positive Results for Udenafil,Its New Long Acting Drug For Erectile Dysfunction 4Calcium Channel Blocker Adalat GITS Offer Additional Benefits 2Calcium Channel Blocker Adalat GITS Offer Additional Benefits 3
Colibri style tips with 0.12 mm, 1 x 2 teeth. Round knurled handle with alignment pin and polished finish.
Stainless steel model of the popular Nordan titanium Colibri forceps. Tying platform with 0.12 mm teeth for grasping delicate structures. Flattened round handle with polished finish.
Also referred to as McLean-Putney suture forceps. Slightly curved 6 mm long platform. Serrated handle with polished finish. Most popular size or model.
Oval solid 15 mm wide lower plate. Open upper plate with inside dimensions 11 mm x 8 mm. Serrated handle with locking thumb screw and polished finish.
Medicine Products: